Neovasc Inc. (NVCN) News
Filter NVCN News Items
NVCN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVCN News Highlights
- For NVCN, its 30 day story count is now at 2.
- Over the past 3 days, the trend for NVCN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest NVCN News From Around the Web
Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.
Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you... |
Neovasc Shareholders Approve Acquisition by Shockwave MedicalVancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement |
Neovasc Announces German Reimbursement RenewalVANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
Shockwave Medical's (SWAV) New Buyout to Boost Patient OutcomeShockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool. |
Dow Dinged As Big Bank Earnings WeighA round of earnings from the banking sector is weighing today, stifling Wall Street's early 2023 momentum. |
Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc AcquisitionShockwave Medical Inc (NASDAQ: SWAV) has agreed to acquire Neovasc Inc (NASDAQ: NVCN) for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million. The upfront cash consideration represents a 27% and 68% premium to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on Jan. 13, 2023. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR), entitlin |
Shockwave Medical to Acquire NeovascVancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Comp |
IIROC Trade Resumption - NVCNTrading resumes in: |
IIROC Trading Halt - NVCNThe following issues have been halted by IIROC: |